Skip to main content
SpringerLink
Log in

Clinical Utilization of Salmon Calcitonin in the Treatment of Osteoporosis

Rationale, Supportive Data, and Considerations for the Future

  • Chapter
Osteoporosis

Part of the book series: Contemporary Endocrinology ((COE))

  • 339 Accesses

Abstract

Calcitonin, a physiologic endogenous inhibitor of bone resorption, decreases osteoclast formation (1,2),osteoclast attachment (2,3),and bone resorption in organ culture and in animal models (1,4,5). Thus there is a rationale for treatment with calcitonin, and specifically salmon calcitonin (S-CT), of diseases associated with increased bone resorption, such as osteoporosis. The last twenty years has witnessed an accumulation of clinical trials with S-CT providing supportive data for such a clinical indication. Also, the ongoing development of newer preparations of S-CT (an oral formulation), and the applicability of S-CT for newer indications (for pain, for hip fracture, etc.) via new clinical trials promises continued usage of this therapeutic agent for the future management of osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Azria M. The Calcitonins: Physiology and Pharmacology. Karger, NY, 1989.

    Google Scholar 

  2. Baron R, Vignery A. Behavior of osteoclasts during a rapid change in their number induced by high doses of parathyroid hormone or calcitonin in intact rats. Metab Bone Dis Relat Res 1981; 2. 339–346.

    Article  CAS  Google Scholar 

  3. Kallio DM, Garant PR, Minkin C. Ultrasound effects of calcitonin on osteoclasts in tissue culture. J Ultrastruct Res 1972; 39: 205–216.

    Article  PubMed  CAS  Google Scholar 

  4. Holtrop ME, Raisz LG, Simmons HA. The effects of parathyroid hormone, colchicine, and calcitonin on the ultrastructure and the activity of osteoclasts in organ culture. J Cell Biol. 1074; 60: 346–355.

    Article  Google Scholar 

  5. Raisz LG. Bone metabolism and its hormonal regulation. Triangle 1983; 22: 83, 84.

    Google Scholar 

  6. Fischer JA, Tobler PH, Kaufmann M, Born W, Henke H, Cooper PE, Sagar M, Martin JB. Calcitonin: Regional distribution of the hormone and its binding sites in the human brain and pituitary. Proc Natl Acad Sci USA 1981; 78: 7801–7805.

    Article  PubMed  CAS  Google Scholar 

  7. Maurer R, Marbach P, Mousson R. Salmon calcitonin binding sites in rat pituitary. Brain Res 1983; 261: 346–348.

    Article  PubMed  CAS  Google Scholar 

  8. Marx SJ, Aurbach GD, Gavin JR, Buell DW. Calcitonin receptors on cultured human lymphocytes. J Biol Chem 1974; 249: 6812–6816.

    PubMed  CAS  Google Scholar 

  9. Munson PL. Physiology and pharmacology of thyrocalcitonin. Proc Natl Acad Sci. USA 1978; 75: 3984–3988.

    Article  Google Scholar 

  10. Agus ZS, Wasserstein A, Goldfarb SI. PTH, calcitonin, cyclic nucleotides and the kidney. Ann Rev Physiol 1981; 43: 583–595.

    Article  CAS  Google Scholar 

  11. Pecile A, Olgiati VR, Sibilia V. Attivitata analgesica di calcitonine di diversa origine. In: Gennari C, Segre G, eds. The effects of calcitonin in man. Proc. 1“ Int. Workshop, Florence, 1982. Masson, Milan, 1983, pp. 205–211.

    Google Scholar 

  12. Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FAO, Martin TJ. Abundant calcitonin receptors in isolated rat osteoclasts. J Clin Invest 1986; 265: 209–215.

    Google Scholar 

  13. Marx SJ, Woodward CJ, Aurbach GD. Calcitonin receptors of kidney and bone. Science 1972; 178: 999–1001.

    Article  PubMed  CAS  Google Scholar 

  14. Baron R, Saffar JL. A quantitative study of the effects of prolonged calcitonin treatment on alveolar bone remodeling in the golden hamster. Calcif Tissue Res 1977; 22: 265–274.

    Article  PubMed  CAS  Google Scholar 

  15. Alam ASMT, Bax CMR, Shankar VS, Bax BE, Bevis PJR, Huang CLH, Moonga BS, Pazianas M, Zaidi M. Further studies on the mode of action of calcitonin on isolated rat osteoclasts: pharmacological evidence for a second site mediating extracellular Cat+ mobilization and cell retraction. J Endocrinol, 1993; 136: 7–15.

    Article  PubMed  CAS  Google Scholar 

  16. Chambers TJ, Jall Ti. Cellular and molecular mechanisms in the regulation and function of osteoclasts. Vitam Horm 1991; 46: 41–86.

    Article  PubMed  CAS  Google Scholar 

  17. Malgaroli A, Meldolesi J, Zambonin-Zallone A, Teti A. Control of cytosolic free calcium in rat and chicken osteoclasts. J Biol Chem 1989;264:14, 342–14, 347.

    Google Scholar 

  18. Moonga BS, Alam ASMT, Bevis PJR, Avaldi F, Soncini R, Huang CLH, Zaldi M.. Regulation of cytosolic free calcium in isolated rat osteoclasts by calcitonin. J Endocrinol 1992; 132: 241–249.

    Article  PubMed  CAS  Google Scholar 

  19. Gravel MR, Zheng ZG, Sims SM, Dixon SJ. Platelet-activating factor induces pseudopod formation in calcitonin-treated rabbit osteoclasts. J Bone Miner Res 1994; 9: 1769–1776.

    Article  PubMed  CAS  Google Scholar 

  20. Zaidi M, Moonga BS, Bevis PJR, Alam ASMT, Legon S, Wimalawansa S, MacIntyre I, Breimer LH. Expression and function of the calcitonin gene products. Vitam Horm 1991; 46: 87–164.

    Article  PubMed  CAS  Google Scholar 

  21. Zheng MH, Fan Y, Wysocki S, Wood DJ, Papadimitriou JM. Carbonic acid anhydrase II gene transcript in cultured osteoclasts from neonatal rats: Effect of calcitonin. Cell Tissue Res 1994; 276: 7–13.

    Article  CAS  Google Scholar 

  22. Berry V, Rathod H, Pulman LB, Datta HK. Immunofluorescent evidence for the abundance of focal adhesion kinase in the human and avian osteoclast and its down regulation by calcitonin. J Endocrinol 1994; 141: R11 - R15.

    Article  PubMed  CAS  Google Scholar 

  23. Kaji H, Sugimoto T, Miyauchi A, Fukase M, Tezuka K, Hakeda Y, Kumegawa M, Chihara K. Calcitonin inhibits osteopontin mRNA expression in isolated rabbit osteoclasts. Endocrinol. 1994; 135: 484–487.

    Article  CAS  Google Scholar 

  24. Hughes DE, Wright KR, Sasaki A, Yoneda T, Uy HL, Roodman GD, Mundy GR, Boyce BF. Bisphosphonates induce osteoclast apoptosis in vivo and in vitro, but calcitonin does not. J Bone Miner Res 1994; 9: B472.

    Google Scholar 

  25. Plotkin LI, Weinstein RS, Parfitt AM, Robertson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104: 1363–1374.

    Article  PubMed  CAS  Google Scholar 

  26. Gruber HE, Ivey JL, Baylink DJ, et al. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 1984; 33: 295–303.

    Article  PubMed  CAS  Google Scholar 

  27. Overgaard K, Rus BJ, Christiansen C, et al. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) 1989; 30: 435–442.

    Article  CAS  Google Scholar 

  28. Overgaard K, Christiansen C. Long-term treatment of established osteoporosis with intranasal calcitonin. Calif Tissue Int 1991; 49: S60 - S63.

    Article  Google Scholar 

  29. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305: 556–561.

    Article  PubMed  CAS  Google Scholar 

  30. Ellerington MC, Hillard TC, Whitcroft SI, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996; 59: 6–11.

    Article  PubMed  CAS  Google Scholar 

  31. Reginster JY, Denis D, Albert A, et al. 1-Year controlled randomized trial of prevention of early postmenopausal bone loss by intrnasal calcitonin. Lancet 1987; 2: 1481–1483.

    Article  PubMed  CAS  Google Scholar 

  32. Reginster JY, Deroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995; 98: 452–458.

    Article  PubMed  CAS  Google Scholar 

  33. Overgaard K, Hansen MA, Nielsen VA, et al. Discontinuous calcitonin treatment of established osteoporosis-effects of withdrawal of treatment. Am J Med 1990; 89: 1–6.

    Article  PubMed  CAS  Google Scholar 

  34. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994; 55: 82–86.

    Article  PubMed  CAS  Google Scholar 

  35. Kraenzlin ME, Seibel MJ, Trechsel U, et al. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment. Calcif Tissue Int 1996; 58: 216–220.

    PubMed  CAS  Google Scholar 

  36. Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992; 305: 1124–1128.

    Article  PubMed  CAS  Google Scholar 

  37. Rico H, Revila M, Hernandez ER, et al. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 1995; 56: 181–185.

    Article  PubMed  CAS  Google Scholar 

  38. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109: 267–276.

    Article  PubMed  CAS  Google Scholar 

  39. McClung MR, Geusens P, Miller PD, Zippel H, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333–340.

    Article  PubMed  CAS  Google Scholar 

  40. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535–1541.

    Article  PubMed  CAS  Google Scholar 

  41. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. J Am Med Assoc 1999; 282 (7): 637–645.

    Article  CAS  Google Scholar 

  42. Chesnut CH, Rosen CJ. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. (editorial), J Bone Min Res 2001; 16: 2163–2172.

    Article  CAS  Google Scholar 

  43. Chesnut CH, Shields AT, et al. How do antiresorptive osteoporosis therapies reduce fracture in the absence of robust effects on bone mineral density (BMD) and remodeling? (abstract) J Bone Min Res 1999;S515:SU335.

    Google Scholar 

  44. Chesnut CH, Majumdar S, et al. The in vitro and in vivo effects of nasal spray salmon calcitonin (NS-CT) on bone quality. (abstract) J Bone Min Res 1999;S516:SU336.

    Google Scholar 

  45. Nagant de Deuxchaisnes C. Calcitonin in the treatment of Paget’ s disease. Triangle 1983; 22: 103–128.

    Google Scholar 

  46. Gennari C, Francini G, Gonelli S, et al. Dolore osseo, endorfine e calcitonine. In: Gennari C, Setre G, eds. The effects of calcitonin in man. Proc. 1st Int. Workshop, Florence 1982. Masson, Milan, 1983, pp. 213–222.

    Google Scholar 

  47. Pun KK, Chan LWL. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clinical Ther, 1989; 11: 205–209.

    CAS  Google Scholar 

  48. Lyritis GP, Tsakalakos N, Magiasis B, et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 1991; 49 (6): 369–372.

    Article  PubMed  CAS  Google Scholar 

  49. Allan E. Calcitonin in the treatment of intractable pain from advanced malignancy. Pharmatherapeutica 1983; 3: 482–486.

    PubMed  CAS  Google Scholar 

  50. Kleibel F, Welzel D, Schmidt G. Acute analgesic effect of salmon calcitonin in patients with bone metastases. Neurosci Lett Suppl 1983; 14: 199.

    Google Scholar 

  51. Eastell R, Mallinak N, Weiss S, et al. Biological variability of serum and urinary n-telopeptides of type 1 collagen in postmenopausal women. J Bone Min Res 2000; 15 (3): 594–598.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Charles H. Chesnut III MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Moïse Azria PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oregon Health & Science University, Portland, OR, USA

    Eric S. Orwoll MD  & Michael Bliziotes MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Chesnut, C.H., Azria, M. (2003). Clinical Utilization of Salmon Calcitonin in the Treatment of Osteoporosis. In: Orwoll, E.S., Bliziotes, M. (eds) Osteoporosis. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-278-4_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-278-4_21

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-260-5

  • Online ISBN: 978-1-59259-278-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation